Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1986 1
1987 3
1990 1
1993 1
1994 3
1995 4
1996 5
1997 13
1998 13
1999 20
2000 29
2001 22
2002 14
2003 19
2004 40
2005 23
2006 36
2007 30
2008 23
2009 23
2010 26
2011 16
2012 17
2013 37
2014 26
2015 16
2016 10
2017 10
2018 14
2019 13
2020 8
2021 8
2022 4
2023 7
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

478 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for cardiol carvedilol
Your search for cardilol-carvedilol retrieved no results
Bisoprolol compared with carvedilol and metoprolol succinate in the treatment of patients with chronic heart failure.
Fröhlich H, Torres L, Täger T, Schellberg D, Corletto A, Kazmi S, Goode K, Grundtvig M, Hole T, Katus HA, Cleland JGF, Atar D, Clark AL, Agewall S, Frankenstein L. Fröhlich H, et al. Clin Res Cardiol. 2017 Sep;106(9):711-721. doi: 10.1007/s00392-017-1115-0. Epub 2017 Apr 22. Clin Res Cardiol. 2017. PMID: 28434020 Free article.
Patients prescribed bisoprolol or carvedilol had similar mortality (HR 0.94, 95% CI 0.82-1.08, p = 0.37). However, there was no significant association between beta-blocker choice and all-cause mortality in any of the matched samples (HR 0.90; 95% CI 0.76-1.06; p = 0.20; H …
Patients prescribed bisoprolol or carvedilol had similar mortality (HR 0.94, 95% CI 0.82-1.08, p = 0.37). However, there was no signi …
Pharmacology of carvedilol.
Dulin B, Abraham WT. Dulin B, et al. Am J Cardiol. 2004 May 6;93(9A):3B-6B. doi: 10.1016/j.amjcard.2004.01.003. Am J Cardiol. 2004. PMID: 15144929 Review.
Carvedilol is a third-generation, neurohormonal antagonist with multiple activities. ...Together, they contribute to the clinical efficacy of carvedilol in a broad spectrum of patient types and may also confer a range of cardioprotective benefits....
Carvedilol is a third-generation, neurohormonal antagonist with multiple activities. ...Together, they contribute to the clinical eff …
Effects of Long-Term Carvedilol Therapy in Patients With ST-Segment Elevation Myocardial Infarction and Mildly Reduced Left Ventricular Ejection Fraction.
Amano M, Izumi C, Watanabe H, Ozasa N, Morimoto T, Bingyuan B, Suwa S, Miyake M, Tamura T, Nakagawa Y, Kadota K, Inuzuka Y, Minamimoto Y, Furukawa Y, Kaji S, Suzuki T, Akao M, Inada T, Kimura T; CAPITAL-RCT Investigators. Amano M, et al. Am J Cardiol. 2023 Jul 15;199:50-58. doi: 10.1016/j.amjcard.2023.04.042. Epub 2023 May 26. Am J Cardiol. 2023. PMID: 37245250 Clinical Trial.
We sought to evaluate the efficacy of beta-blocker therapy in patients with STEMI with mildly reduced LVEF. In the CAPITAL-RCT (Carvedilol Post-Intervention Long-Term Administration in Large-Scale Randomized Controlled Trial), patients with STEMI with successful percutaneo …
We sought to evaluate the efficacy of beta-blocker therapy in patients with STEMI with mildly reduced LVEF. In the CAPITAL-RCT (Carvedilo …
Meta-Analysis of Carvedilol for the Prevention of Anthracycline-Induced Cardiotoxicity.
Kheiri B, Abdalla A, Osman M, Haykal T, Chahine A, Ahmed S, Osman K, Hassan M, Bachuwa G, Bhatt DL. Kheiri B, et al. Am J Cardiol. 2018 Dec 1;122(11):1959-1964. doi: 10.1016/j.amjcard.2018.08.039. Epub 2018 Sep 8. Am J Cardiol. 2018. PMID: 30292333 Review.
Therefore, we conducted a meta-analysis of all randomized controlled trials to evaluate the efficacy of carvedilol for the primary prevention of anthracycline-induced cardiotoxicity. ...Our results showed significantly reduced rates of low LVEF favoring the carvedilol …
Therefore, we conducted a meta-analysis of all randomized controlled trials to evaluate the efficacy of carvedilol for the primary pr …
Carvedilol overdose.
Hantson P, Lambermont JY, Simoens G, Mahieu P. Hantson P, et al. Acta Cardiol. 1997;52(4):369-71. Acta Cardiol. 1997. PMID: 9381894
Carvedilol is a non selective beta-adrenoceptor antagonist which also causes peripheral vasodilation primarily via alpha 1-adrenergic blockade (Strein et al., 1987, McTavish et al., 1993). ...
Carvedilol is a non selective beta-adrenoceptor antagonist which also causes peripheral vasodilation primarily via alpha 1-adrenergic …
Mapping the journey.
Stevenson LW, Lewis E. Stevenson LW, et al. J Am Coll Cardiol. 2006 Apr 18;47(8):1612-4. doi: 10.1016/j.jacc.2006.01.054. Epub 2006 Mar 29. J Am Coll Cardiol. 2006. PMID: 16630998 Free article. Review. No abstract available.
Comparative effects of nebivolol and carvedilol on left ventricular diastolic function in older patients with heart failure and preserved ejection fraction.
Park K, Park TH. Park K, et al. Int J Cardiol Cardiovasc Risk Prev. 2023 Jul 28;18:200201. doi: 10.1016/j.ijcrp.2023.200201. eCollection 2023 Sep. Int J Cardiol Cardiovasc Risk Prev. 2023. PMID: 37575339 Free PMC article.
Patients were randomized into a carvedilol group or a nebivolol group. Transthoracic echocardiography was performed at baseline and 12 months by the same investigator who was blinded to clinical data. ...This study showed no superiority of nebivolol over carvedilol …
Patients were randomized into a carvedilol group or a nebivolol group. Transthoracic echocardiography was performed at baseline and 1 …
Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial.
Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR Jr, das Dores Cruz F, Gonçalves Brandão SM, Rigaud VOC, Higuchi-Dos-Santos MH, Hajjar LA, Kalil Filho R, Hoff PM, Sahade M, Ferrari MSM, de Paula Costa RL, Mano MS, Bittencourt Viana Cruz CB, Abduch MC, Lofrano Alves MS, Guimaraes GV, Issa VS, Bittencourt MS, Bocchi EA. Avila MS, et al. J Am Coll Cardiol. 2018 May 22;71(20):2281-2290. doi: 10.1016/j.jacc.2018.02.049. Epub 2018 Mar 11. J Am Coll Cardiol. 2018. PMID: 29540327 Free article. Clinical Trial.
A significant difference existed between groups in troponin I levels over time, with lower levels in the carvedilol group (p = 0.003). Additionally, a lower incidence of diastolic dysfunction was noted in the carvedilol group (p = 0.039). ...(Carvedilol Effec …
A significant difference existed between groups in troponin I levels over time, with lower levels in the carvedilol group (p = 0.003) …
Carvedilol in the failing heart.
Lombardi WL, Gilbert EM. Lombardi WL, et al. Clin Cardiol. 2001 Dec;24(12):757-66. doi: 10.1002/clc.4960241202. Clin Cardiol. 2001. PMID: 11768738 Free PMC article. Review.
Patients with chronic heart failure due to left ventricular systolic dysfunction of ischemic or nonischemic etiology have shown improvement in morbidity and mortality with carvedilol therapy. In patients with symptomatic (New York Heart Association class II-IV) heart failu …
Patients with chronic heart failure due to left ventricular systolic dysfunction of ischemic or nonischemic etiology have shown improvement …
478 results